David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Elisrasib Demonstrates High DCR in KRAS G12C NSCLC

Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival

Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy

Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity